Data of the CL patients evaluated for HLA-G and IL-10 protein expression
Patient no. . | Gender . | Age, y . | Histologic classification (EORTC) . | Stage . | HLA-G protein expression . | IL-10 expression . |
---|---|---|---|---|---|---|
BL1 | M | 75 | Follicular B-cell lymphoma | ++ | + | |
BL2 | M | 32 | Follicular B-cell lymphoma | ++ | − | |
BL3 | M | 19 | Follicular B-cell lymphoma | + | − | |
BL4 | M | 59 | Follicular B-cell lymphoma | + | ++ | |
BL5 | M | 58 | MZBCL | ++ | ++ | |
BL6 | F | 82 | Diffuse large B-cell lymphoma | + | + | |
BL7 | F | 81 | Diffuse large B-cell lymphoma | − | ND | |
BL8 | M | 49 | Diffuse large B-cell lymphoma | + | ND | |
BL9 | F | 77 | Large B-cell lymphoma of the leg | − | − | |
BL10 | M | 57 | T-cell-rich B-cell lymphoma | − | − | |
TL1 | F | 36 | Lymphomatoid papulosis | − | − | |
TL2 | M | 45 | Lymphomatoid papulosis | − | − | |
TL3 | M | 65 | Lymphomatoid papulosis | − | − | |
TL4 | M | 54 | Lymphomatoid papulosis | − | − | |
TL5 | M | 52 | Lymphomatoid papulosis | − | − | |
TL6 | M | 40 | MF | Ia | − | − |
TL7 | M | 56 | MF | Ib | − | − |
TL8 | F | 87 | MF | Ib | − | − |
TL9 | F | 64 | MF | Ib | − | − |
TL10 | M | 66 | MF | IIb | − | − |
TL11 | M | 74 | MF | IIb | − | − |
TL12 | F | 52 | MF | IIb | − | − |
TL13 | M | 55 | MF | III | ++ | ++ |
TL14 | F | 77 | MF | IVb | + | + |
TL15 | F | 87 | Sézary syndrome | IVa | − | − |
TL16 | F | 45 | CD8+ initial CTCL | Ia | + | + |
TL17 | F | 50 | CD8+, TIA-1+, CD30− large cell CTCL | IIb | ++ | ++ |
TL18 | F | 68 | CD30+ large cell CTCL | IIb | + | − |
TL19 | F | 56 | CD30+ large cell CTCL | IIb | − | − |
TL20 | F | 67 | CD30+large cell CTCL | IIb | + | − |
TL21 | F | 29 | CD30+ large cell CTCL | IIb | − | − |
TL22 | F | 45 | CD30+ large cell CTCL | IIb | − | − |
TL23 | F | 33 | CD30−large cell CTCL | IIb | − | − |
TL24 | M | 18 | CD30− large cell CTCL | IIb | ++ | − |
TL25 | M | 65 | CD30− large cell CTCL‡ | IIb | ++ | + |
TL26 | M | 76 | CD30− large cell CTCL‡ | IVb | ++ | ++ |
TL27 | F | 36 | CD30− large cell CTCL‡ | IVb | − | − |
TL28 | F | 50 | CD30− large cell CTCL‡ | IVb | ++ | + |
TL29 | M | 69 | CD30+ pleomorphic CTCL | IIb | − | − |
TL30 | M | 62 | CD30+pleomorphic CTCL | IVa | + | + |
TL31 | M | 52 | CD30− pleomorphic small/medium-sized CTCL | IIb | ++ | + |
TL32 | M | 80 | CD30− pleomorphic small/medium-sized CTCL | IIb | + | + |
TL33 | M | 62 | CD30− pleomorphic small/medium-sized CTCL | IIb | + | + |
TL34 | M | 50 | CD30− pleomorphic small/medium-sized CTCL | IVb | + | − |
TL35 | M | 28 | GSS | IIb | ++ | ++ |
Patient no. . | Gender . | Age, y . | Histologic classification (EORTC) . | Stage . | HLA-G protein expression . | IL-10 expression . |
---|---|---|---|---|---|---|
BL1 | M | 75 | Follicular B-cell lymphoma | ++ | + | |
BL2 | M | 32 | Follicular B-cell lymphoma | ++ | − | |
BL3 | M | 19 | Follicular B-cell lymphoma | + | − | |
BL4 | M | 59 | Follicular B-cell lymphoma | + | ++ | |
BL5 | M | 58 | MZBCL | ++ | ++ | |
BL6 | F | 82 | Diffuse large B-cell lymphoma | + | + | |
BL7 | F | 81 | Diffuse large B-cell lymphoma | − | ND | |
BL8 | M | 49 | Diffuse large B-cell lymphoma | + | ND | |
BL9 | F | 77 | Large B-cell lymphoma of the leg | − | − | |
BL10 | M | 57 | T-cell-rich B-cell lymphoma | − | − | |
TL1 | F | 36 | Lymphomatoid papulosis | − | − | |
TL2 | M | 45 | Lymphomatoid papulosis | − | − | |
TL3 | M | 65 | Lymphomatoid papulosis | − | − | |
TL4 | M | 54 | Lymphomatoid papulosis | − | − | |
TL5 | M | 52 | Lymphomatoid papulosis | − | − | |
TL6 | M | 40 | MF | Ia | − | − |
TL7 | M | 56 | MF | Ib | − | − |
TL8 | F | 87 | MF | Ib | − | − |
TL9 | F | 64 | MF | Ib | − | − |
TL10 | M | 66 | MF | IIb | − | − |
TL11 | M | 74 | MF | IIb | − | − |
TL12 | F | 52 | MF | IIb | − | − |
TL13 | M | 55 | MF | III | ++ | ++ |
TL14 | F | 77 | MF | IVb | + | + |
TL15 | F | 87 | Sézary syndrome | IVa | − | − |
TL16 | F | 45 | CD8+ initial CTCL | Ia | + | + |
TL17 | F | 50 | CD8+, TIA-1+, CD30− large cell CTCL | IIb | ++ | ++ |
TL18 | F | 68 | CD30+ large cell CTCL | IIb | + | − |
TL19 | F | 56 | CD30+ large cell CTCL | IIb | − | − |
TL20 | F | 67 | CD30+large cell CTCL | IIb | + | − |
TL21 | F | 29 | CD30+ large cell CTCL | IIb | − | − |
TL22 | F | 45 | CD30+ large cell CTCL | IIb | − | − |
TL23 | F | 33 | CD30−large cell CTCL | IIb | − | − |
TL24 | M | 18 | CD30− large cell CTCL | IIb | ++ | − |
TL25 | M | 65 | CD30− large cell CTCL‡ | IIb | ++ | + |
TL26 | M | 76 | CD30− large cell CTCL‡ | IVb | ++ | ++ |
TL27 | F | 36 | CD30− large cell CTCL‡ | IVb | − | − |
TL28 | F | 50 | CD30− large cell CTCL‡ | IVb | ++ | + |
TL29 | M | 69 | CD30+ pleomorphic CTCL | IIb | − | − |
TL30 | M | 62 | CD30+pleomorphic CTCL | IVa | + | + |
TL31 | M | 52 | CD30− pleomorphic small/medium-sized CTCL | IIb | ++ | + |
TL32 | M | 80 | CD30− pleomorphic small/medium-sized CTCL | IIb | + | + |
TL33 | M | 62 | CD30− pleomorphic small/medium-sized CTCL | IIb | + | + |
TL34 | M | 50 | CD30− pleomorphic small/medium-sized CTCL | IVb | + | − |
TL35 | M | 28 | GSS | IIb | ++ | ++ |
− indicates no expression detectable with 4H84 mAb, accordingly for IL-10; +, single-cell immunoreactivity with 4H84 mAb, accordingly for IL-10; ++, strong immunoreactivity with 4H84 mAb, accordingly for IL-10; and ND, not done.
Skin material was available for quantitative PCR.
PBMCs were available for quantitative PCR.
Transformed from MF.